Evidence map›Paper›PMID 28683720›Full record

Trial reportBMC infectious diseases2017

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.

Delphine Sculier, Angèle Gayet-Ageron, Manuel Battegay, Matthias Cavassini, Jan Fehr, Cedric Hirzel, Patrick Schmid, Enos Bernasconi, Alexandra Calmy, Swiss HIV Cohort Study

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. The role of rilpivirine in Southern Africa.Southern African journal of HIV medicine · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Delphine SculierDivision of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland. delphine.sculier@hcuge.ch.
Angèle Gayet-AgeronClinical Research Center and Division of Clinical Epidemiology, Department of Health and Community Medicine, University Hospital Geneva, Geneva, Switzerland.
Manuel BattegayDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Matthias CavassiniDivision of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.
Jan FehrDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Cedric HirzelUniversity Clinic of Infectious Diseases, University Hospital Bern, Bern, Switzerland.
Patrick SchmidDivision of Infectious Diseases and Hospital Epidemiology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland.
Enos BernasconiDivision of Infectious Diseases, Ospedale Regionale, Lugano, Switzerland.
Alexandra CalmyDivision of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland.
Swiss HIV Cohort Study
University Hospital of Geneva · CHUniversity of St.Gallen · CHUniversity of Zurich · CHOspedale regionale di Lugano · CHUniversity Hospital of Basel · CHUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study and to assess its effectiveness and safety over a 24 months period.

methodsAll individuals enrolled in the Swiss HIV Cohort Study who initiated a RPV/TDF/FTC co-formulation between April 2013 and March 2014 were included. Primary outcomes were the HIV-RNA viral load (copies/mL) and CD4 cell count (cells/mm

resultsOf 644 individuals who started the RPV/TDF/FTC co-formulation, only 7.5% were treatment-naïve. At 24 months, viral suppression (HIV-RNA <50 copies/mL) was achieved in 100% and 96.7% of cART-naïve and cART-experienced patients respectively. The switch to RPV was mainly done for simplification (44.6%) and to overcome central nervous system toxicity symptoms due to efavirenz (24%). Six months after switch, 74.8% of patients reported an improvement of psycho-neurological symptoms with continued improvement at 12 months for almost 80%. However, one quarter of patients reported a discontinuation of RPV/TDF/FTC on October 30, 2015 after a median time of 18.4 months. Reasons for discontinuation included physician decision (5.3%) and side-effects (3.9%) mainly related to the central nervous system and to renal toxicity.

conclusionThe RPV/TDF/FTC co-formulation was safe and effective throughout 24 months of follow-up but barely prescribed for HIV-naïve patients. Despite excellent virological suppression among both treatment-naïve and -experienced patients, we observed a high rate of treatment discontinuation.

Indexed as

AdultAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCD4 Lymphocyte CountCyclopropanesDrug CombinationsEmtricitabineFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedProspective StudiesAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesDrug CombinationsefavirenzEmtricitabineRilpivirineTenofovirFirst-line regimenHIV-1RilpivirineSafetyTreatment simplificationVirological response

Identifiers

PMID28683720
PMCPMC5500925
OpenAlexW2729471497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.